Identification of chromosome aberrations in sporadic microsatellite stable and unstable colorectal cancers using array comparative genomic hybridization

Cancer Genetics

Volumn 204, Issue 2, 2011, Pages 84-95

  Dyrsø, Thomas ^a,d   Li, Jian ^b   Wang, Kai ^b   Lindebjerg, Jan ^c,d   Kølvraa, Steen ^a,d   Bolund, Lars ^b   Jakobsen, Anders ^c,d   Bruun Petersen, Gert ^a   Li, Shengting ^b   Crüuger, Dorthe G ^a,d  

^a LILLEBAELT HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c Department of Clinical Pathology ^*  (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Array CGH; Chromosome instability; Colorectal cancer; Microsatellite instability; Microsatellite stability

Indexed keywords

PROTEIN P53; MICROSATELLITE DNA;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER STAGING; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CLINICAL ASSESSMENT; COLORECTAL CANCER; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; GENE DELETION; GENE FUNCTION; GENE LOCATION; GENE LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROSATELLITE INSTABILITY; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; PATHOLOGY;

AGED; AGED, 80 AND OVER; CHROMOSOME ABERRATIONS; COLORECTAL NEOPLASMS; COMPARATIVE GENOMIC HYBRIDIZATION; FEMALE; HUMANS; MALE; MICROSATELLITE INSTABILITY; MICROSATELLITE REPEATS; MIDDLE AGED;

EID: 79958255986     PISSN: 22107762     EISSN: 22107770     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.08.019     Document Type: Article

References (96)

1. Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319: 525-532.
2. Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759-767.
3. Thiagalingam S, Lengauer C, Leach FS, et al. Evaluation of candidate tumour suppressor genes on chromosome 18 in colorectal cancers. Nat Genet 1996;13:343-346.
4. Bodmer WF, Bailey CJ, Bodmer J, et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature 1987;328:614-616.
5. Fearon ER, Cho KR, Nigro JM, et al. Identification of a chromosome 18q gene that is altered in colorectal cancers. Science (NY) 1990;247:49-56.
6. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science (NY) 1989;244:217-221.
7. McCoy MS, Toole JJ, Cunningham JM, et al. Characterization of a human colon/lung carcinoma oncogene. Nature 1983;302:79-81.
8. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-649.
9. Jass JR, Whitehall VL, Young J, et al. Emerging concepts in colorectal neoplasia. Gastroenterology 2002;123:862-876.
10. Liu B, Nicolaides NC, Markowitz S, et al. Mismatch repair gene defects in sporadic colorectal cancers with microsatellite instability. Nat Genet 1995;9:48-55.
11. Lengauer C, Kinzler KW, Vogelstein B. Genetic instability in colorectal cancers. Nature 1997;386:623-627.
12. Jones AM, Douglas EJ, Halford SE, et al. Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinoma. Oncogene 2005; 24:118-129.
13. Hawkins NJ, Tomlinson I, Meagher A, et al. Microsatellitestable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. Br J Cancer 2001;84: 232-236.
14. Giaretti W, Venesio T, Sciutto A, et al. Near-diploid and neartriploid human sporadic colorectal adenocarcinomas differ for KRAS2 and TP53 mutational status. Genes Chromosomes Cancer 2003;37:207-213.
15. Grady WM. Genomic instability and colon cancer. Cancer metastasis reviews 2004;23:11-27.
16. Harley CB, Futcher AB, Greider CW. Telomeres shorten during ageing of human fibroblasts. Nature 1990;345:458-460.
17. Benn PA. Specific chromosome aberrations in senescent fibroblast cell lines derived from human embryos. Am J Human Genet 1976;28:465-473.
18. Blackburn EH. Telomere states and cell fates. Nature 2000;408: 53-56.
19. Hastie ND, Dempster M, Dunlop MG, et al. Telomere reduction in human colorectal carcinoma and with ageing. Nature 1990; 346:866-868.
20. Mathieu N, Pirzio L, Freulet-Marriere MA, et al. Telomeres and chromosomal instability. Cell Mol Life Sci 2004;61:641-656.
21. Lane DP. Cancer. A death in the life of p53. Nature 1993;362: 786-787.
22. Smith ML, Chen IT, Zhan Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science (NY) 1994;266:1376-1380.
23. Douglas EJ, Fiegler H, Rowan A, et al. Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. Cancer Res 2004;64:4817-4825.
24. Nakao K, Mehta KR, Fridlyand J, et al. High-resolution analysis of DNA copy number alterations in colorectal cancer by arraybased comparative genomic hybridization. Carcinogenesis 2004;25:1345-1357.
25. Camps J, Armengol G, del Rey J, et al. Genome-wide differences between microsatellite stable and unstable colorectal tumors. Carcinogenesis 2006;27:419-428.
26. Lassmann S, Weis R, Makowiec F, et al. Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal- and microsatellite-unstable sporadic colorectal carcinomas. J Mol Med 2007;85:293-304.
27. Snijders AM, Segraves R, Blackwood S, et al. BAC microarraybased comparative genomic hybridization. Methods Mol Biol 2004;256:39-56.
28. Hubbard TJ, Aken BL, Beal K, et al. Ensembl 2007. Nucleic Acids Res 2007;35:D610-D617.
29. Olshen AB, Venkatraman ES, Lucito R, et al. Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 2004;5:557-572.
30. Willenbrock H, Fridlyand J. A comparison study: applying segmentation to array CGH data for downstream analyses. Bioinformatics 2005;21:4084-4091.
31. Jensen LH, Cruger DG, Lindebjerg J, et al. Laser microdissection and microsatellite analysis of colorectal adenocarcinomas. Anticancer research 2006;26:2069-2074.
32. Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of internationalcriteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998;58:5248-5257.
33. Ionov Y, Peinado MA, Malkhosyan S, et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-561.
34. Jass JR. Pathogenesis of colorectal cancer. Surg Clin N Am 2002;82:891-904.
35. De Angelis PM, Stokke T, Beigi M, et al. Prognostic significance of recurrent chromosomal aberrations detected by comparative genomic hybridization in sporadic colorectal cancer. Int J Colorect Dis 2001;16:38-45.
36. Meijer GA, Hermsen MA, Baak JP, et al. Progression from colorectal adenoma to carcinoma is associated with non-random chromosomal gains as detected by comparative genomic hybridisation. J Clin Pathol 1998;51:901-909.
37. Ried T, Knutzen R, Steinbeck R, et al. Comparative genomic hybridization reveals a specific pattern of chromosomal gains and losses during the genesis of colorectal tumors. Genes Chromosomes Cancer 1996;15:234-245.
38. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science (NY) 1993; 260:1317-1320.
39. Eng C, Crossey PA, Mulligan LM, et al. Mutations in the RET proto-oncogene and the von Hippel-Lindau disease tumour suppressor gene in sporadic and syndromic phaeochromocytomas. J Med Genet 1995;32:934-937.
40. Kuzmin I, Duh FM, Latif F, et al. Identification of the promoter of the human von Hippel-Lindau disease tumor suppressor gene. Oncogene 1995;10:2185-2194.
41. Whitney M, Thayer M, Reifsteck C, et al. Microcell mediated chromosome transfer maps the Fanconi anaemia group D gene to chromosome 3p. Nat Genet 1995;11:341-343.
42. Sekido Y, Ahmadian M, Wistuba II, et al. Cloning of a breast cancer homozygous deletion junction narrows the region of search for a 3p21.3 tumor suppressor gene. Oncogene 1998;16: 3151-3157.
43. Sundaresan V, Chung G, Heppell-Parton A, et al. Homozygous deletions at 3p12 in breast and lung cancer. Oncogene 1998;17: 1723-1729.
44. Hesson LB, Cooper WN, Latif F. Evaluation of the 3p21.3 tumoursuppressor gene cluster. Oncogene 2007;26:7283-7301.
45. Lerman MI, Minna JD. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The International Lung Cancer Chromosome 3p21.3 Tumor Suppressor Gene Consortium. Cancer Res 2000;60:6116-6133.
46. Carritt B, Kok K, van den Berg A, et al. A gene from human chromosome region 3p21 with reduced expression in small cell lung cancer. Cancer Res 1992;52:1536-1541.
47. Kok K, Hofstra R, Pilz A, et al. A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme. Proc Natl Acad Sci USA 1993;90:6071-6075.
48. Lee SY, Lee SY, Choi Y. TRAF-interacting protein (TRIP): a novel component of the tumor necrosis factor receptor (TNFR)- and CD30-TRAF signaling complexes that inhibits TRAF2-mediated NF-kappaB activation. J Exp Med 1997;185:1275-1285.
49. Bao S, Shen X, Shen K, et al. The mammalian Rad24 homologous to yeast Saccharomyces cerevisiae Rad24 and Schizosaccharomyces pombe Rad17 is involved in DNA damage checkpoint. Cell Growth Differ 1998;9:961-967.
50. Parker AE, Van de Weyer I, Laus MC, et al. Identification of a human homologue of the Schizosaccharomyces pombe rad17+ checkpoint gene. J Biol Chem 1998;273:18340-18346.
51. Bao S, Chang MS, Auclair D, et al. HRad17, a human homologue of the Schizosaccharomyces pombe checkpoint gene rad17, is overexpressed in colon carcinoma. Cancer Res 1999; 59:2023-2028.
52. von Deimling F, Scharf JM, Liehr T, et al. Human and mouse RAD17 genes: identification, localization, genomic structure and histological expression pattern in normal testis and seminoma. Human Genet 1999;105:17-27.
53. Wang X, Wang L, Callister MD, et al. Human Rad17 is phosphorylated upon DNA damage and also overexpressed in primary non-small cell lung cancer tissues. Cancer Res 2001;61: 7417-7421.
54. Zhao M, Begum S, Ha PK, et al. Downregulation of RAD17 in head and neck cancer. Head Neck 2008;30:35-42.
55. Ando-Akatsuka Y, Saitou M, Hirase T, et al. Interspecies diversity of the occludin sequence: cDNA cloning of human, mouse, dog, and rat-kangaroo homologues. The J Cell Biol 1996;133:43-47.
56. Furuse M, Hirase T, Itoh M, et al. Occludin: a novel integral membrane protein localizing at tight junctions. J Cell Biol. 1993; 123(6 Pt 2):1777-1788.
57. Soler AP, Miller RD, Laughlin KV, et al. Increased tight junctional permeability is associated with the development of colon cancer. Carcinogenesis 1999;20:1425-1431.
58. Kimura Y, Shiozaki H, Hirao M, et al. Expression of occludin, tight-junction-associated protein, in human digestive tract. Am J Pathol 1997;151:45-54.
59. Tobioka H, Isomura H, Kokai Y, et al. Polarized distribution of carcinoembryonic antigen is associated with a tight junction molecule in human colorectal adenocarcinoma. J Pathol 2002; 198:207-212.
60. Resnick MB, Konkin T, Routhier J, et al. Claudin-1 is a strong prognostic indicator in stage II colonic cancer: a tissue microarray study. Mod Pathol 2004;18:511-518.
61. Billings SD, Walsh SV, Fisher C, et al. Aberrant expression of tight junction-related proteins ZO-1, claudin-1 and occludin in synovial sarcoma: an immunohistochemical study with ultrastructural correlation. Mod Pathol 2004;17:141-149.
62. Morita K, Tsukita S, Miyachi Y. Tight junction-associated proteins (occludin, ZO-1, claudin-1, claudin-4) in squamous cell carcinoma and Bowen's disease. Br J Dermatol 2004;151: 328-334.
63. Papadopoulos MC, Saadoun S, Woodrow CJ, et al. Occludin expression in microvessels of neoplastic and non-neoplastic human brain. Neuropathol Appl Neurobiol 2001;27:384-395.
64. Tobioka H, Isomura H, Kokai Y, et al. Occludin expression decreases with the progression of human endometrial carcinoma. Hum Pathol 2004;35:159-164.
65. Osanai M, Murata M, Nishikiori N, et al. Epigenetic silencing of occludin promotes tumorigenic and metastatic properties of cancer cells via modulations of unique sets of apoptosisassociated genes. Cancer Res 2006;66:9125-9133.
66. Osanai M, Murata M, Nishikiori N, et al. Occludin-mediated premature senescence is a fail-safe mechanism against tumorigenesis in breast carcinoma cells. Cancer Sci 2007;98: 1027-1034.
67. Maul RS, Chang DD. EPLIN, epithelial protein lost in neoplasm. Oncogene 1999;18:7838-7841.
68. Maul RS, Song Y, Amann KJ, et al. EPLIN regulates actin dynamics by cross-linking and stabilizing filaments. J Cell Biol 2003;160:399-407.
69. Su GH, Bansal R, Murphy KM, et al. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci USA 2001;98:3254-3257.
70. ten Dijke P, Ichijo H, Franzen P, et al. Activin receptor-like kinases: a novel subclass of cell-surface receptors with predicted serine/threonine kinase activity. Oncogene 1993;8:2879-2887.
71. Pereira G, Schiebel E. Separase regulates INCENP-Aurora B anaphase spindle function through Cdc14. Science (NY) 2003; 302:2120-2124.
72. Shepard JL, Amatruda JF, Finkelstein D, et al. A mutation in separase causes genome instability and increased susceptibility to epithelial cancer. Genes Dev 2007;21:55-59
73. Zou H, McGarry TJ, Bernal T, et al. Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis. Science (NY) 1999;285:418-422.
74. Song H, Li Y, Chen G, et al.HumanMCRS2,a cell-cycle-dependent protein, associates with LPTS/PinX1 and reduces the telomere length. Biochem Biophys Res Commun 2004;316:1116-1123.
75. Mori K, Maeda Y, Kitaura H, et al. MM-1, a novel c-Mycassociating protein that represses transcriptional activity of c-Myc. J Biol Chem 1998;273:29794-29800.
76. Fleischer TC, Yun UJ, Ayer DE. Identification and characterization of three new components of the mSin3A corepressor complex. Mol Cell Biol 2003;23:3456-3467.
77. David G, Turner GM, Yao Y, et al. mSin3-associated protein, mSds3, is essential for pericentric heterochromatin formation and chromosome segregation in mammalian cells. Genes Dev 2003;17:2396-2405.
78. O'Regan L, Blot J, Fry AM. Mitotic regulation by NIMA-related kinases. Cell Div 2007;2:25.
79. Husmann K, Sers C, Fietze E, et al. Transcriptional and translational downregulation of H-REV107, a class II tumour suppressor gene located on human chromosome 11q11-12. Oncogene 1998;17:1305-1312.
80. Sers C, Husmann K, Nazarenko I, et al. The class II tumour suppressor gene H-REV107-1 is a target of interferon-regulatory factor-1 and is involved in IFNgamma-induced cell death in human ovarian carcinoma cells. Oncogene 2002;21:2829-2839.
81. Nakamura Y, Larsson C, Julier C, et al. Localization of the genetic defect in multiple endocrine neoplasia type 1 within a small region of chromosome 11. Am J Hum Genet 1989;44:751-755.
82. Thakker RV, Bouloux P, Wooding C, et al. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med 1989;321:218-224.
83. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science NY 1996;271:350-353.
84. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331: 213-221.
85. Shibata D, Reale MA, Lavin P, et al. The DCC protein and prognosis in colorectal cancer. N Engl J Med 1996;335: 1727-1732.
86. Buffart TE, Coffa J, Hermsen MA, et al. DNA copy number changes at 8q11-24 in metastasized colorectal cancer. Cell Oncol 2005;27:57-65.
87. Tanami H, Tsuda H, Okabe S, et al. Involvement of cyclin D3 in liver metastasis of colorectal cancer, revealed by genome-wide copy-number analysis. Lab Invest 2005;85:1118-1129.
88. Kim MY, Yim SH, Kwon MS, et al. Recurrent genomic alterations with impact on survival in colorectal cancer identified by genome-wide array comparative genomic hybridization. Gastroenterology 2006;131:1913-1924.
89. Collins S, Groudine M. Amplification of endogenous myc-related DNA sequences in a human myeloid leukaemia cell line. Nature 1982;298:679-681.
90. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science (NY) 1998;281: 1509-1512.
91. Ioannidis P, Mahaira L, Papadopoulou A, et al. 8q24 Copy number gains and expression of the c-myc mRNA stabilizing protein CRD-BP in primary breast carcinomas. Int J Cancer 2003;104:54-59.
92. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science (NY) 2002;297: 102-104.
93. Sansom OJ, Meniel VS, Muncan V, et al. Myc deletion rescues Apc deficiency in the small intestine. Nature 2007;446:676-679.
94. Shachaf CM, Kopelman AM, Arvanitis C, et al. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer. Nature 2004;431:1112-1117.
95. Yokota J, Tsunetsugu-Yokota Y, Battifora H, et al. Alterations of myc, myb, and rasHa proto-oncogenes in cancers are frequent and show clinical correlation. Science (NY) 1986;231:261-265.
96. Georgiades IB, Curtis LJ, Morris RM, et al. Heterogeneity studies identify a subset of sporadic colorectal cancers without evidence for chromosomal or microsatellite instability. Oncogene 1999;18:7933-7940.